Biogen narrows FY2026 adjusted EPS guidance to $15.95-$16.75

Biogen narrowed its FY2026 adjusted EPS guidance from $15.85-$16.85 to $15.95-$16.75, versus the $12.36 estimate. Q3 adjusted EPS came in at $2.62 (est. $1.98) on revenue of $2.804B (est. $2.632B).

Detected & updated continuously · Source: Nebula